GOVX vs. AADI, STTK, CTMX, VHAQ, CNTX, QNCX, KRON, UNCY, ONCY, and IOBT
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Aadi Bioscience (AADI), Shattuck Labs (STTK), CytomX Therapeutics (CTMX), Viveon Health Acquisition (VHAQ), Context Therapeutics (CNTX), Quince Therapeutics (QNCX), Kronos Bio (KRON), Unicycive Therapeutics (UNCY), Oncolytics Biotech (ONCY), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs.
GeoVax Labs (NASDAQ:GOVX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
GeoVax Labs received 13 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 96.00% of users gave GeoVax Labs an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
GeoVax Labs has higher earnings, but lower revenue than Aadi Bioscience.
In the previous week, Aadi Bioscience had 2 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for Aadi Bioscience and 1 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
GeoVax Labs has a beta of 3.28, suggesting that its stock price is 228% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
GeoVax Labs currently has a consensus price target of $14.20, suggesting a potential upside of 747.76%. Aadi Bioscience has a consensus price target of $1.67, suggesting a potential downside of 40.26%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than Aadi Bioscience.
GeoVax Labs has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat GeoVax Labs' return on equity.
Summary
GeoVax Labs beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free GOVX Stock Alerts